Genomed Spólka Akcyjna (WSE:GEN)
Poland flag Poland · Delayed Price · Currency is PLN
27.80
-1.00 (-3.47%)
At close: Dec 5, 2025

Genomed Spólka Akcyjna Company Description

Genomed Spólka Akcyjna provides DNA sequencing and analysis and diagnostics services for congenital diseases in Poland.

It develops molecular diagnostics based on DNA sequencing for the application of prophylactics and treatment, such as replacement or gene therapy.

The company’s diagnostic services include DNA isolation, PCR amplification of chosen DNA regions, comparison of the sequences, and interpretation of the results by diagnosticians.

It also provides various types of DNA sequence analysis, including polymorphism analysis or sequencing of phage genetic material or bacteria genomes; and next-generation sequencing and genetic counseling services.

In addition, the company offers DNA oligonucleotides synthesis, RNA oligonucleotides and peptide synthesis, various nucleotide modifications, and the 4LAB automated pipetting workstation, as well as laboratory equipment through e-store.

It serves scientific institutes, universities, hospitals, and biotechnological and pharmaceutical companies, as well as healthcare networks and individual customers.

The company was founded in 2007 and is based in Warsaw, Poland.

Genomed Spólka Akcyjna
Country Poland
Founded 2007
Industry In Vitro and In Vivo Diagnostic Substances
Employees 54
CEO Anna Boguszewska-Chachulska

Contact Details

Address:
ul. Ponczowa 12
Warsaw, 02-971
Poland
Phone 48 22 644 6019
Website genomed.pl

Stock Details

Ticker Symbol GEN
Exchange Warsaw Stock Exchange
Fiscal Year January - December
Reporting Currency PLN
SIC Code 2835

Key Executives

Name Position
Anna Boguszewska-Chachulska Chief Executive Officer